https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/accounts-payable https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/accounts-receivable https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/accretion-amortization-of-discounts-and-premiums-investments https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/accrual-provision https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/accrued-income-taxes-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/accrued-liabilities-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/accrued-marketing-costs-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/accrued-professional-fees-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/accumulated-depreciation https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/acquired-finite-lived-intangible-asset-amount https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/acquired-intangible-assets-other-than-goodwill https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/acquisition-acquisition-related-costs https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/acquisition-consideration-transferred https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/acquisition-contingent-consideration-liability https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/acquisitions https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/additional-paid-in-capital https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/adjustments-related-to-tax-withholding-for-share-based-compensation https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/allowance-for-doubtful-accounts-receivable https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/allowance-for-doubtful-accounts-receivable-write-offs https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/amortization https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/amortization-of-deferred-charges https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/amortization-of-financing-costs https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/amount-recognized-in-net-periodic-benefit-cost-and-oci-before-tax https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/aoci https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/asset-impairment-charges https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/assets-fair-value-disclosure-recurring https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/available-for-sale-securities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/basic-shares https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/business-acquisition-contingent-consideration-at-fair-value-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/buybacks-share-repurchases https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/buybacks-treasury-stock-cost https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/capital-expenditures https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/capital-lease-obligations-incurred https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/cash-and-cash-equivalents-fair-value-disclosure https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/cash-and-equivalents https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/cash-fdic-insured-amount https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/cash-flow-breakdown https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/commitments-and-contingencies https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/common-stock-value https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/comprehensive-income https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/concentration-risk-percentage https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/contracts-revenue https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/contractual-obligation-due-in-next-twelve-months https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/cost-of-goods-sold https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/costs-and-expenses https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/cumulative-effect-of-new-accounting-principle-in-period-of-adoption https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/current-assets https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/current-federal-tax-expense-benefit https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/current-foreign-tax-expense-benefit https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/current-income-tax-expense-benefit https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/current-liabilities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/current-state-and-local-tax-expense-benefit https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/debt-basis-spread-on-variable-rate https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/debt-interest-rate-stated-percentage https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/debt-maturing-after-year-five https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/debt-maturing-in-next-twelve-months https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/debt-maturing-in-year-five https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/debt-maturing-in-year-four https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/debt-maturing-in-year-three https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/debt-maturing-in-year-two https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/decrease-in-restricted-cash https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/decrease-in-utb-is-reasonably-possible https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-costs https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-costs-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-costs-current-and-noncurrent https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-federal-income-tax-expense-benefit https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-foreign-income-tax-expense-benefit https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-income-tax-expense-benefit https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-income-tax-liabilities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-rent-credit-noncurrent https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-revenue https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-revenue-2 https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-revenue-noncurrent https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-revenue-revenue-recognized https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-state-and-local-income-tax-expense-benefit https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-deferred-income https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-gross https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-in-process-research-and-development https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-inventory https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-liabilities-net-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-liabilities-net-noncurrent https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-net-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-net-noncurrent https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-operating-loss-carryforwards-domestic https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-operating-loss-carryforwards-foreign https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-operating-loss-carryforwards-not-subject-to-expiration https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-operating-loss-carryforwards-subject-to-expiration https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-other https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-property-plant-and-equipment https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-state-taxes https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-tax-credit-carryforwards https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-tax-deferred-expense https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-tax-deferred-expense-compensation-and-benefits-employee-benefits https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-tax-deferred-expense-compensation-and-benefits-employee-compensation https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-liabilities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-liabilities-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-liabilities-deferred-expense-capitalized-inventory-costs https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-liabilities-goodwill-and-intangible-assets-intangible-assets https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-liabilities-investments https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-liabilities-noncurrent https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-liabilities-other https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/deferred-tax-liabilities-property-plant-and-equipment https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-accumulated-oci-before-tax https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-accumulated-oci-net-gains-losses-before-tax https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-accumulated-oci-net-prior-service-cost-credit-after-tax https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-actual-return-on-plan-assets https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-actuarial-gain-loss https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-amortization-of-gains-losses https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-amount-to-be-amortized-from-accumulated-oci-next-fiscal-year https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-amounts-recognized-in-oci-net-gain-loss-before-tax https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-assumptions-used-calculating-benefit-obligation-discount-rate https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-assumptions-used-calculating-benefit-obligation-rate-of-compensation-increase https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-assumptions-used-calculating-net-periodic-benefit-cost-discount-rate https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-assumptions-used-calculating-net-periodic-benefit-cost-expected-long-term-return-on-assets https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-assumptions-used-calculating-net-periodic-benefit-cost-rate-of-compensation-increase https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-benefit-obligation https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-benefits-paid https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-contributions-by-employer https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-contributions-by-plan-participants https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-expected-future-benefit-payments-five-fiscal-years-thereafter https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-expected-future-benefit-payments-next-twelve-months https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-expected-future-benefit-payments-year-five https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-expected-future-benefit-payments-year-four https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-expected-future-benefit-payments-year-three https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-expected-future-benefit-payments-year-two https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-expected-return-on-plan-assets https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-fair-value-of-plan-assets https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-funded-status-of-plan https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-future-amortization-of-gain-loss https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-interest-cost https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-net-periodic-benefit-cost https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-pension-plans-with-accumulated-benefit-obligations-in-excess-of-plan-assets-aggregate-accumulated-benefit-obligation https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-pension-plans-with-accumulated-benefit-obligations-in-excess-of-plan-assets-aggregate-fair-value-of-plan-assets https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-pension-plans-with-accumulated-benefit-obligations-in-excess-of-plan-assets-aggregate-projected-benefit-obligation https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-plan-amendments https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-service-cost https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plan-weighted-average-asset-allocations https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/defined-benefit-plans-estimated-future-employer-contributions-in-next-fiscal-year https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/depreciation https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/depreciation-and-amortization-expense https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/diluted-shares https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/dividends-cash https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/dividends-paid https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/effective-tax-rate https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/employee-related-liabilities-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/eps https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/eps-basic https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/estimate-of-possible-loss https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/excess-tax-benefit-from-share-based-compensation-financing-activities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/excess-tax-benefit-from-share-based-compensation-operating-activities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/exchange-rate-effect-on-cash https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/fair-value-of-assets-acquired https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/financing-cash-flow https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-next-twelve-months https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-year-five https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-year-four https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-year-three https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-year-two https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/finite-lived-intangible-assets-foreign-currency-translation-gain-loss https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/finite-lived-intangible-assets-net https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/finitelived-intangible-assets-acquired https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/foreign-currency-transaction-gain-loss-unrealized https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/foreign-pretax-income https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/gain-loss-on-disposition-of-assets https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/gain-loss-on-disposition-of-assets-1 https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/gain-loss-on-sale-of-property-plant-equipment https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/gain-loss-related-to-litigation-settlement https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/gains-losses-on-extinguishment-of-debt https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/general-and-administrative-expense https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/goodwill https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/goodwill-acquired https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/goodwill-foreign-currency-translation-gain-loss https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/goodwill-other-changes https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/gross-profit https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/guaranty-liabilities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/impairment-of-intangible-assets-excluding-goodwill https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/impairment-of-intangible-assets-finitelived https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/impairment-of-intangible-assets-indefinitelived-excluding-goodwill https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/incentive-from-lessor https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/income-tax https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/income-tax-examination-interest-expense https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/income-taxes-paid https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/income-taxes-receivable https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-decrease-in-accrued-liabilities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-decrease-in-deferred-charges https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-decrease-in-deferred-income-taxes https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-decrease-in-deferred-revenue https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-decrease-in-income-taxes https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-decrease-in-interest-payable-net https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-decrease-in-inventories https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-decrease-in-notes-receivables https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-decrease-in-other-accrued-liabilities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-decrease-in-other-operating-capital-net https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-decrease-in-other-receivables https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-decrease-in-prepaid-taxes https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-decrease-in-property-and-other-taxes-payable https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-decrease-in-restricted-cash https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-decrease-in-unbilled-receivables https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/increase-in-restricted-cash https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/incremental-common-shares-attributable-to-conversion-of-debt-securities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/incremental-common-shares-attributable-to-conversion-of-preferred-stock https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/incremental-common-shares-attributable-to-share-based-payment-arrangements https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/indefinite-lived-intangible-assets-excluding-goodwill https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/indefinite-lived-intangible-assets-translation-adjustments https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/insider-transactions-other https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/insider-transactions-preferred https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/insider-transactions-stock-options https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/insider-transactions-stock-options/purchases https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/intangible-assets-net-including-goodwill https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/interest-expense https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/interest-on-convertible-debt-net-of-tax https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/interest-paid https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/interest-paid-capitalized https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/interest-payable-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/inventory https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/inventory-finished-goods https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/inventory-noncurrent https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/inventory-raw-materials https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/inventory-work-in-process https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/investing-cash-flow https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/investment-income-interest https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/lease-and-rental-expense https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/liability-for-uncertain-tax-positions-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/liability-for-uncertain-tax-positions-noncurrent https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/loans-payable-to-bank https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/loans-pledged-as-collateral https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/long-term-investments https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/long-term-notes-payable https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/net-cash-from-financing-activities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/net-cash-from-investing-activities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/net-cash-from-operating-activities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/net-change-in-cash https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/net-income https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/net-income-loss-attributable-to-parent-diluted https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/noncash-or-part-noncash-acquisition-intangible-assets-acquired https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/noncash-or-part-noncash-acquisition-payables-assumed https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/noncurrent-assets https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/notes-and-loans-receivable-net-noncurrent https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/notes-issued https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/notes-payable https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/notes-payable-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/notes-payable-fair-value-disclosure https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/number-of-operating-segments https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/number-of-reportable-segments https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/number-of-reporting-units https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/oci-amortization-adjustment-from-aoci-pension-and-other-postretirement-benefit-plans-for-net-prior-service-cost-credit-tax https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/oci-before-reclassifications-net-of-tax https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/oci-defined-benefit-plans-net-unamortized-gain-loss-arising-net-of-tax https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax-change https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/oci-pension-and-other-postretirement-benefit-plans-net-unamortized-gain-loss-arising-before-tax https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/oci-reclassification-adjustment-from-aoci-pension-and-other-postretirement-benefit-plans-for-net-gain-loss-before-tax https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/oci-unrealized-holding-gain-loss-on-securities-arising-net-of-tax https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/operating-cash-flow https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/operating-income https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/operating-lease-liability-noncurrent https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/operating-lease-payments-due https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/operating-lease-payments-due-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/operating-lease-payments-due-thereafter https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/operating-leases-future-minimum-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/operating-leases-rent-expense-net https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/operating-loss-carryforwards https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/origination-of-notes-receivable-from-related-parties https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/other-accrued-liabilities-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/other-accrued-liabilities-current-and-noncurrent https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/other-accrued-liabilities-noncurrent https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/other-current-liabilities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/other-income https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/other-noncash-income https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/other-noncash-income-expense https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/other-noncurrent-assets https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/other-noncurrent-liabilities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/other-nonoperating-expense https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/other-nonoperating-income-expense https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/other-notes-payable https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/other-operating-income-expense-net https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/other-receivables-gross-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/other-receivables-net-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/other-sales-revenue-net https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/other-sundry-liabilities-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/paid-in-capital-share-based-compensation-stock-options-requisite-service-period-recognition https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/paid-in-capital-tax-effect-from-share-based-compensation https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/paid-in-kind-interest https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/payments-for-capital-improvements https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/payments-for-legal-settlements https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/payments-for-proceeds-from-other-investing-activities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/payments-for-restructuring https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/payments-to-acquire-intangible-assets https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/payments-to-acquire-investments https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/payments-to-acquire-notes-receivable https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/payments-to-acquire-other-investments https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/pension-and-other-postretirement-defined-benefit-plans-liabilities-noncurrent https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/preferred-shares-facts https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/preferred-stock-shares-authorized https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/preferred-stock-shares-issued https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/preferred-stock-value https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/pretax-income-domestic https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/pretax-income-minority-interest-and-income-loss-from-equity-method-investments https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/proceeds-from-income-tax-refunds https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/proceeds-from-notes-payable https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/proceeds-from-payments-for-other-financing-activities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/proceeds-from-repayments-of-notes-payable https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/proceeds-from-sale-and-maturity-of-other-investments https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/proceeds-from-sale-maturity-and-collections-of-investments https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/proceeds-from-sale-of-other-investments https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/proceeds-from-sale-of-property-plant-and-equipment https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/proceeds-from-stock-issued https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/proceeds-from-stock-options-exercised https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/proceeds-from-stock-plans https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/property-plant-equipment https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/public-float https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/purchase-commitment-remaining-minimum-amount-committed https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/range-of-possible-loss-maximum https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/realized-investment-gains-losses https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/related-party-transaction-amounts-of-transaction https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/related-party-transaction-expenses-from-transactions-with-related-party https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/repayments-of-notes-payable https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/research-and-development https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/research-and-development-arrangement-contract-to-perform-for-others-compensation-earned https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/research-and-development-in-process https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/restricted-cash-and-cash-equivalents https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/restricted-cash-and-cash-equivalents-at-carrying-value https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/restricted-cash-and-cash-equivalents-noncurrent https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/restructuring-and-related-cost-cost-incurred-to-date https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/restructuring-charges https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/restructuring-reserve https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/restructuring-reserve-translation-adjustment https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/retained-earnings https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/revenue https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/revenue-recognition-milestone-method-revenue-recognized https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/royalty-revenue https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/sales-and-excise-tax-payable-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/sales-and-excise-tax-payable-current-and-noncurrent https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/sales-revenue-goods-net https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/selling-and-marketing-expense https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/severance-costs https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/shareholders-equity https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/shares-authorized https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/shares-issued https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/shares-issued-shares-espps https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/short-term-investments https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/significant-change-in-utb-is-reasonably-possible-amount-of-unrecorded-benefit https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/significant-purchase-commitment-remaining-minimum-amount-committed https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/stock-award-fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/stock-award-fair-value-assumptions-expected-volatility-rate-maximum https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/stock-award-fair-value-assumptions-expected-volatility-rate-minimum https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/stock-award-fair-value-assumptions-risk-free-interest-rate-maximum https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/stock-award-fair-value-assumptions-risk-free-interest-rate-minimum https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/stock-based-compensation https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/stock-compensation-unrecognized-cost https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/stock-compensation-unrecognized-cost-stock-options https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/stock-issued-shares-issued-value-espp https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/stock-issued-value-of-shares-issued-for-acquisitions https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/stock-options-exercisable-number https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/stock-options-exercises-in-period-total-intrinsic-value https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/stock-options-vested-and-expected-to-vest-exercisable-average-exercise-price https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-credit-carryforward-amount https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-rate-reconciliation-change-in-enacted-tax-rate https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-rate-reconciliation-disposition-of-business https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-rate-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-rate-reconciliation-nondeductible-expense https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-rate-reconciliation-nondeductible-expense-share-based-compensation-cost https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-rate-reconciliation-repatriation-of-foreign-earnings https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-rate-reconciliation-tax-contingencies https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-rate-reconciliation-tax-contingencies-other https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-rate-reconciliation-tax-credits-foreign https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-rate-reconciliation-tax-credits-other https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-reconciliation-tax-credits-research https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-reconciliation-tax-settlements-foreign https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/tax-withholding-on-stock-awards https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/taxes-payable-current https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/total-assets https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/total-liabilities https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/trading-securities-realized-gain https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/trading-securities-realized-gain-loss https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/treasury-stock-shares https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/treasury-stock-value https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/unbilled-contracts-receivable https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/unrecognized-tax-benefits https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/utb-change https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/utb-decrease-from-settlements https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/utb-income-tax-penalties-and-interest-expense https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/utb-increase-from-current-year-positions https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/utb-increase-from-prior-year-positions https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/utb-interest-on-income-taxes-expense https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/utb-that-would-impact-effective-tax-rate https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/valuation-allowances-and-reserves-charged-to-cost-and-expense https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/valuation-allowances-and-reserves-deductions https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/value-of-shares-issued-for-stock-awards https://stock.noler.com/us/stock/sucampo-pharmaceuticals-inc/weighted-average-number-of-share-outstanding-basic-and-diluted